These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 19770692)

  • 21. Efficient neutralization of primary isolates by the plasma from HIV-1 infected Indian children.
    Prakash SS; Chaudhary AK; Lodha R; Kabra SK; Vajpayee M; Hazarika A; Bagga B; Luthra K
    Viral Immunol; 2011 Oct; 24(5):409-13. PubMed ID: 22004138
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of the maturation of neutralizing antibodies on human immunodeficiency virus (HIV) envelope evolution in HIV-infected subjects.
    Zhao J; Nie J; Jiao Y; Li L; Zhang T; Liu Q; Huang W; Wu H; Wang Y
    Infect Genet Evol; 2016 Mar; 38():82-89. PubMed ID: 26706846
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of neutralizing antibodies in HIV infection.
    Humbert M; Dietrich U
    AIDS Rev; 2006; 8(2):51-9. PubMed ID: 16848273
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Autologous neutralizing antibodies and viral load in HIV-2-infected individuals.
    Tamalet C; Simon F; Dhiver C; Matheron S; de Micco P; Gastao JA; Brun-Vézinet F
    AIDS; 1995 Jan; 9(1):90-1. PubMed ID: 7893447
    [No Abstract]   [Full Text] [Related]  

  • 25. Inter-subtype cross-neutralizing antibodies recognize epitopes on cell-associated HIV-1 virions.
    Donners H; Davis D; Willems B; van der Groen G
    J Med Virol; 2003 Feb; 69(2):173-81. PubMed ID: 12683404
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neutralization and infectivity characteristics of envelope glycoproteins from human immunodeficiency virus type 1 infected donors whose sera exhibit broadly cross-reactive neutralizing activity.
    Cham F; Zhang PF; Heyndrickx L; Bouma P; Zhong P; Katinger H; Robinson J; van der Groen G; Quinnan GV
    Virology; 2006 Mar; 347(1):36-51. PubMed ID: 16378633
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neutralizing monoclonal antibodies to human immunodeficiency virus type 1 do not inhibit viral transcytosis through mucosal epithelial cells.
    Chomont N; Hocini H; Gody JC; Bouhlal H; Becquart P; Krief-Bouillet C; Kazatchkine M; Bélec L
    Virology; 2008 Jan; 370(2):246-54. PubMed ID: 17920650
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HIV-1 cross-neutralizing antibodies in German HIV-1-infected patients do not correlate with an antibody-binding pattern against different HIV-1 isolates.
    Jurkiewicz E; Petry H; Sutor GC; Lang S; Schedel I; Hunsmann G
    AIDS; 1995 Jan; 9(1):91-3. PubMed ID: 7893448
    [No Abstract]   [Full Text] [Related]  

  • 29. Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission.
    Derdeyn CA; Decker JM; Bibollet-Ruche F; Mokili JL; Muldoon M; Denham SA; Heil ML; Kasolo F; Musonda R; Hahn BH; Shaw GM; Korber BT; Allen S; Hunter E
    Science; 2004 Mar; 303(5666):2019-22. PubMed ID: 15044802
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lack of autologous neutralizing antibody to human immunodeficiency virus type 1 (HIV-1) and macrophage tropism are associated with mother-to-infant transmission.
    Lathey JL; Tsou J; Brinker K; Hsia K; Meyer WA; Spector SA
    J Infect Dis; 1999 Aug; 180(2):344-50. PubMed ID: 10395848
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Orally exposed uninfected individuals have systemic anti-HIV responses associating with partners' viral load.
    Hasselrot K; Bratt G; Hirbod T; Säberg P; Ehnlund M; Lopalco L; Sandström E; Broliden K
    AIDS; 2010 Jan; 24(1):35-43. PubMed ID: 19779318
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A longitudinal study of neutralizing antibodies and disease progression in HIV-1-infected subjects.
    Cecilia D; Kleeberger C; Muñoz A; Giorgi JV; Zolla-Pazner S
    J Infect Dis; 1999 Jun; 179(6):1365-74. PubMed ID: 10228056
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Residual viraemia in HIV-1-infected patients with plasma viral load Ostrowski SR; Katzenstein TL; Pedersen BK; Gerstoft J; Ullum H
    Scand J Immunol; 2008 Dec; 68(6):652-60. PubMed ID: 19055701
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HIV-1 viral load and CD4 cell count in untreated children with vertically acquired asymptomatic or mild disease. Paediatric European Network for Treatment of AIDS (PENTA).
    AIDS; 1998 Mar; 12(4):F1-8. PubMed ID: 9520161
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Broadly Neutralizing Antibody Responses in a Subset of HIV-1-Infected Individuals in Chennai, India.
    Hussain SI; Panneerselvam N; Solomon S; Solomon SS; Adam K; Chandrasekaran E; Montefiori DC; Pachamuthu B
    J Int Assoc Provid AIDS Care; 2017; 16(2):201-208. PubMed ID: 23422744
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plasma levels of viro-immunological markers in HIV-infected and non-infected Ethiopians: correlation with cell surface activation markers.
    Messele T; Brouwer M; Girma M; Fontanet AL; Miedema F; Hamann D; Rinke de Wit TF
    Clin Immunol; 2001 Feb; 98(2):212-9. PubMed ID: 11161977
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increase in neutralizing antibody titer against sequential autologous HIV-1 isolates after 16 weeks saquinavir (Invirase) treatment.
    Sarmati L; Nicastri E; el-Sawaf G; Ventura L; Salanitro A; Ercoli L; Vella S; Andreoni M
    J Med Virol; 1997 Dec; 53(4):313-8. PubMed ID: 9407377
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relationships among the detection of p24 antigen, human immunodeficiency virus (HIV) RNA level, CD4 cell count, and disease progression in HIV-infected individuals with hemophilia.
    Sabin CA; Lepri AC; Devereux H; Phillips AN; Loveday C; Lee CA
    J Infect Dis; 2001 Aug; 184(4):511-4. PubMed ID: 11471111
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Temporal development and prognostic value of antibody response to the major neutralizing epitopes of gp120 during HIV-1 infection.
    Turbica I; Simon F; Besnier JM; LeJeune B; Choutet P; Goudeau A; Barin F
    J Med Virol; 1997 Jul; 52(3):309-15. PubMed ID: 9210041
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genome-wide association study on the development of cross-reactive neutralizing antibodies in HIV-1 infected individuals.
    Euler Z; van Gils MJ; Boeser-Nunnink BD; Schuitemaker H; van Manen D
    PLoS One; 2013; 8(1):e54684. PubMed ID: 23372753
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.